Rani Therapeutics Holdings recently announced a collaboration and license agreement with Chugai Pharmaceutical for the joint development and commercialization of an oral product combining Rani’s ...

Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is one of the hot stocks to buy with huge upside potential. On October 21, H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics ...

Rani Therapeutics Holdings Inc. Annual cash flow by MarketWatch. View RANI net cash flow, operating cash flow, operating expenses and cash dividends.

) has been revised to $9.44 / share. This is a decrease of 11.90% from the prior estimate of $10.71 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...

Rani Therapeutics Holdings, Inc. (RANI) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions ...

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has ...

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and ...